Trial Profile
A pilot study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] for the primary treatment of ALK-ve [anaplastic lymphoma kinase-negative] peripheral T cell lymphoma [non-Hodgkin's lymphoma]
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2006
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions
- 06 Dec 2006 Status change
- 05 Dec 2006 New trial record.